Novartis’ prostate cancer drug secures FDA breakthrough designation
An investigational radioligand therapy, 177Lu-PSMA-617 is intended for precision cancer treatment. It is a combination of a targeting compound (ligand) and a therapeutic radioisotope. On administration into the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.